The ADC OQY-3258 Demonstrates Early Efficacy in Multiple Breast Cancer Subtypes
The investigational anti-TROP2 antibody-drug conjugate (ADC) OQY-3258 (ESG401) displayed preliminary activity in multiple breast cancer subtypes, according to findings from a phase 1a/1b trial (NCT04892342). Data presented during the 2024 ESMO Congress …